CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal ...

Axsome Therapeutics has begun the Phase 3 CLARITY trial of solriamfetol in adults with major depressive disorder and excessive daytime sleepiness. The study focuses on a patient group that currently ...

DMT therapy significantly reduced major depressive disorder symptoms in a phase IIa trial. Learn more about this rapid-acting ...

Credit: Otsuka. At this time, the product is available to patients for a discounted price of $50; the full price is $200. Rejoyn ™, the first prescription digital therapeutic cleared for the treatment ...

Major depressive disorder (MDD) is a disturbance of mood that may have persistent and long-term consequences impacting patients’ overall level of functioning and quality of life. 1 Historically, ...

A new study suggests wrist-worn sleep trackers may help predict depression relapse weeks early—explore what this means for ...

Major depressive disorder (MDD) is among the most common psychiatric disorders, affecting approximately 330 people worldwide.

Seltorexant is an investigational selective antagonist of the human orexin-2 receptor. Seltorexant, an investigational selective orexin-2 receptor antagonist, was associated with statistically ...

A single dose of the psychedelic drug dimethyltryptamine (DMT), given with psychological support, rapidly reduced depressive ...